Orion Corporation (GB:0M2O)
LSE:0M2O
0M2O Stock Chart & Stats
€70.85
-€0.32(-0.73%)
At close: 4:00 PM EST
€70.85
-€0.32(-0.73%)
Day’s Range― - ―
52-Week Range€56.55 - €75.40
Previous CloseN/A
Volume5.12K
Average Volume (3M)29.18K
Market Cap
€9.85B
Enterprise Value€9.12B
Total Cash (Recent Filing)€259.40M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)18.6
Beta0.97
Next Earnings
Jul 17, 2026EPS Estimate
0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.47
Shares Outstanding109,609,535
10 Day Avg. Volume23,736
30 Day Avg. Volume29,180
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€72.00Price Target Upside1.62% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
EarningsNubeqa is expected to drive consensus EPS upgrades, improving Orion's ability to raise the dividend, which is crucial for local investors.
Product PortfolioOpevesostat (ODM-208) could sustain growth into the 2030s, with potential peak sales of €1.1 billion and Orion eligible to receive $1.6 billion in milestones.
Sales OutlookNubeqa's peak sales are projected to reach €1.3 billion, backed by Bayer's optimistic outlook, positive doctor feedback, and strong IQVIA script trends.
Bears Say
CompetitionNubeqa faces competition from Xtandi and Erleada, although it is preferred by doctors for better tolerability and flexibility in use with comorbidities.
Orion Corporation News
0M2O FAQ
What was Orion Corporation’s price range in the past 12 months?
Orion Corporation lowest share price was €56.55 and its highest was €75.40 in the past 12 months.
What is Orion Corporation’s market cap?
Orion Corporation’s market cap is €9.85B.
When is Orion Corporation’s upcoming earnings report date?
Orion Corporation’s upcoming earnings report date is Jul 17, 2026 which is in 19 days.
How were Orion Corporation’s earnings last quarter?
Orion Corporation released its earnings results on Apr 23, 2026. The company reported €0.64 earnings per share for the quarter, missing the consensus estimate of €0.712 by -€0.072.
Is Orion Corporation overvalued?
According to Wall Street analysts Orion Corporation’s price is currently Undervalued.
Does Orion Corporation pay dividends?
Orion Corporation does not currently pay dividends.
What is Orion Corporation’s EPS estimate?
Orion Corporation’s EPS estimate is 0.96.
How many shares outstanding does Orion Corporation have?
Orion Corporation has 109,609,535 shares outstanding.
What happened to Orion Corporation’s price movement after its last earnings report?
Orion Corporation reported an EPS of €0.64 in its last earnings report, missing expectations of €0.712. Following the earnings report the stock price went down -6.597%.
Which hedge fund is a major shareholder of Orion Corporation?
Currently, no hedge funds are holding shares in GB:0M2O
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orion Corporation
Orion Oyj is a global pharmaceutical company engaged in the research, development, manufacturing, and commercialization of human and veterinary medicines, alongside active pharmaceutical ingredients (APIs). Its market reach extends across Finland, the Nordic countries, wider Europe, North America, and other international territories. The company's human health division offers both prescription drugs and self-care products. Its key prescription medications include Nubeqa for prostate cancer treatment, dexdor and Precedex for intensive care sedation, and therapies like Stalevo and Comtess/Comtan for Parkinson's disease. Other significant human products are Simdax for acute decompensated heart failure and Fareston for breast cancer. Orion also provides a comprehensive suite of Easyhaler-branded drugs, such as Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol, all designed to treat asthma and chronic obstructive pulmonary disease (COPD). In the animal health sector, Orion offers veterinary pharmaceuticals including Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. Beyond its own product line, the company manufactures APIs for both generic and proprietary drugs and provides contract manufacturing services. Orion also acts as a distributor, marketing and selling veterinary medicines produced by other international companies. Its customer base is broad, serving various healthcare providers and professionals, including specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as direct consumers with pets. Orion Oyj fosters strategic partnerships, notably with Propeller Health to embed connectivity into its Easyhaler® portfolio for asthma and COPD, and a research collaboration and license agreement with Alligator Bioscience AB (publ) focusing on the discovery and advancement of innovative bispecific antibody cancer therapeutics. Founded in 1917, Orion Oyj is headquartered in Espoo, Finland.
0M2O Stock 12 Month Forecast
Average Price Target
€72.00
▲(1.62% Upside)
Technical Analysis
Options Prices
Currently, No data available
---